Additionally, combining the BRG1/BRM ATPase inhibitor FHD-286 with VTP50469 reduces AML burden and improves survival in both MLL1r and NPM1 mutant patient-derived xenograft models than MI alone [197]. The gene discussed is NPM1; the disease is acute myeloid leukemia.